# BioNTech

> BioNTech is a VC fund in Mainz backing Biotechnology and Health Care. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Mainz, Germany
- Total investments: 6
- Last investment: Jun 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/biontech-ag
- X (Twitter): https://twitter.com/BioNTech_Group
- Website: http://www.biontech.de
- Facebook: https://www.facebook.com/pages/BioNTech-AG/

BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates.

## Contacts

5 contacts available for BioNTech. Shizune tracks 8 team members at BioNTech. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biontech-ag?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Post-IPO Equity | $21M–$29M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Health Care | 3 | 50% |
| Medical | 2 | 33% |
| Therapeutics | 2 | 33% |
| Pharmaceutical | 2 | 33% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 2 | 33% |
| Pre-Seed | 1 | 17% |
| Series B | 1 | 17% |
| Funding Round | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 3 | 50% |
| Germany | 2 | 33% |
| Poland | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Annemarie Hanekamp | Chief Commercial Officer | 0 | https://shizune.co/investors/profile/annemarie-hanekamp-7efc |
| Arvind m. Hundal Ph.d. | SVP Business Development | 0 | https://shizune.co/investors/profile/arvind-m-hundal |
| Christoph Huber | Cofounder & deputy chair supervisory board | 0 | https://shizune.co/investors/profile/christoph-huber |
| Christoph Kröner | Director DNA Process Development & Cap Technology | 0 | https://shizune.co/investors/profile/christoph-kr%C3%B6ner |
| Jesse Dong | Vice President, Peptide Chemistry | 0 | https://shizune.co/investors/profile/jesse-dong |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sortera Bio | Sortera Bio operates as a biotechnology company. Sortera is committed to providing revolutionary solutions in biologics discovery. | $10.2M | Pre-Seed | Jun 05, 2025 |  |
| Crescendo Biologics | Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $32M |  | Jul 24, 2023 |  |
| Greenforce | Greenforce creates and sells plant-based foods that are good for both people and the environment. Its products are 100% vegan, made with high-quality raw materials sourced from reputable suppliers, and the entire value chain is transparent. It aims to secure the protein supply for future generations, who cannot be fed animal proteins. | $13.7M | Venture - Series Unknown | Dec 07, 2022 |  |
| Ryvu | Ryvu is a biopharmaceutical company developing small-molecule therapies that address the clinical limitations of current treatments in oncology. | $20.8M | Post-IPO Equity | Nov 30, 2022 |  |
| MediGene | MediGene is a company that specializes in biotechnology specifically in the treatment of cancer. | $29.4M | Post-IPO Equity | Feb 21, 2022 |  |
| InstaDeep | InstaDeep is an EMEA leader in decision-making AI products for the Enterprise, with headquarters in London, and offices in Paris, Tunis, Lagos, Dubai and Cape Town. With expertise in both machine intelligence research and concrete business deployments, the Company provides a competitive advantage to its partners in an AI-first world. Leveraging itsextensive knowhow in GPU-accelerated computing, deep learning and reinforcement learning, InstaDeep has built products, such as its novel DeepChain™ platform, that tackle the most complex challenges across a range of industries. InstaDeep has also developed collaborations with global leaders in the Artificial Intelligence ecosystem, such as Google DeepMind, NVIDIA and Intel. The Company is part of Intel’s AI Builders program and was named an Elite Preferred Deep Learning Partner by NVIDIA | $100M | Series B | Jan 25, 2022 |  |

6 of 6 investments shown.

## Co-investors
- [Alpha Intelligence Capital](https://shizune.co/investors/profile/alpha-intelligence-capital) — VC Fund, 1 deal together
- [AstraZeneca](https://shizune.co/investors/profile/astrazeneca) — VC Fund, 1 deal together
- [BayWa](https://shizune.co/investors/profile/baywa-ag) — VC Fund, 1 deal together
- [BayWa Venture](https://shizune.co/investors/profile/baywa-venture) — VC Fund, 1 deal together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 1 deal together
- [CDIB Capital](https://shizune.co/investors/profile/cdib-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Blue Horizon Corporation](https://shizune.co/investors/profile/blue-horizon-corporation) — VC Fund
- [CircleUp](https://shizune.co/investors/profile/circleup-growth-partners) — VC Fund

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Organic Food VC Funds in Germany](https://shizune.co/investors/organic-food-vc-funds-germany)

## FAQ

### What does BioNTech invest in?

BioNTech invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is BioNTech's check size?

BioNTech typically joins rounds of $21M–$29M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioNTech participates in.

### How do I contact BioNTech?

Public channels for BioNTech include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BioNTech?

The team at BioNTech includes Annemarie Hanekamp (Chief Commercial Officer), Arvind m. Hundal Ph.d. (SVP Business Development) and Christoph Huber (Cofounder & deputy chair supervisory board), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co